Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Cellular Goods boosts team with five appointments

12 Apr 2021 07:00

RNS Number : 0615V
Cellular Goods PLC
12 April 2021
 

12 April 2021

 

 Cellular Goods PLC

("Cellular Goods" or "the Company")

 

Cellular Goods strengthens team with five new appointments

 

Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products based on biosynthetic cannabinoids, is pleased to announce that it has appointed a new Head of Process and Applied Sciences, made two senior hires to its product development team and contracted two expert consultants to advise on the development of the Company's pet care and skincare ranges.

Istok Nahtigal joins as Head of Process and Applied Sciences to focus on Cellular Goods' cannabinoid supply chain and will be responsible for optimising the Company's relationships with its manufacturing partners. Istok is a Chartered Chemist and cannabis industry expert in the field of fermentation and bio-extractions. He has an impressive track record and his work has led to multiple inventions and patents in cannabinoid purification. Previously, Istok was a key scientific member of LAVVAN, a pioneering company focused on commercialising high-quality cannabinoid ingredients using synthetic biology, and MedReleaf Corp, one of the first Canadian producers of medical cannabis to receive a license from Health Canada. Prior to this, he held the role of Process Scientist at Bionche Life Sciences, leading the group evolving novel fermentation and downstream purification schemes for an E.coli vaccine.

Amanda Pape and Melissa Santolini join the product development team as Senior Quality Assurance Manager and Lead Project Manager respectively and will support Cellular Goods' product development, quality assurance, and roll out. Amanda is a healthcare professional with over 15 years of experience working in hospital diagnostic laboratories who has transferred her expertise to the cannabis industry. In 2020 Amanda founded her own quality assurance consulting company, working collaboratively with cannabis licensed providers to implement regulatory requirements and Quality Management Systems. Prior to this, she was also the Quality Assurance Manager at LAVVAN. Melissa has experience in the cannabis, pharmaceutical and agrochemical sectors. She was most recently at LAVVAN, where she focused on driving regulatory, product development and quality initiatives. Prior to LAVVAN, Melissa led product chemistry projects as a chemist at UPL Ltd, a global provider of crop protection chemicals, and held an analytical R&D role at Apotex Pharmachem Inc, a division of the Apotex group of companies.

Caroline Queen has been appointed as Pet Care Advisor and will provide consultancy regarding the development of Cellular's pet care range. This will include identifying suitable applications for cannabinoids in pet products and meeting associated regulatory and veterinary requirements. Caroline has an extensive background in the clinical and veterinary industry. She was formerly the Senior Business Development Director at Vet Partners Ltd, a veterinary group providing centralised support to individual practices across the UK.

Antony Buck has been appointed as Skincare Business Adviser and will be providing consultancy regarding the development of the Company's skincare range which will launch this year. In 2000 Antony created REN Skincare, a multi-award-winning brand that is sold in 50 countries and has a committed consumer base, with its range being sold predominantly in specialty stores and pharmacies. Antony successfully grew REN into a global brand with annual turnover excess of £40m before selling the business to Unilever in 2015.

Alexis Abraham, Chief Executive of Cellular Goods, commented: "Cellular Goods is executing on our differentiated business strategy: one focused on delivering clarity and consistent quality for consumers and leading the fast-moving consumer goods cannabinoid market through science and brand expertise. I am very pleased to welcome Istok, Caroline, Amanda, Melissa, and Antony. In their respective areas they complement our world-class team and will be a huge asset as we continue product development and gear up to releasing the first items in our skincare line this autumn." 

 

 

Cellular Goods

Alexis Abraham

Chief Executive

 

Neil Thapar

Investor Relations

+44 207 031 6871

 

 

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

Corporate Broker

Colin Rowbury

Jon Belliss

 

+44 207 399 9427 

 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Edward Daly

Salamander Davoudi

cellulargoods@tancredigroup.com

+44 744 922 6720

+44 786 143 0057

+44 795 754 9906

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGZGMDMMKGMZZ
Date   Source Headline
13th Mar 20097:00 amPRNIssue of Equity
30th Jan 20099:06 amPRNTotal Voting Rights
29th Dec 20087:00 amPRNIssue of Equity
11th Dec 20084:31 pmPRNAlteration to Loan Notes
3rd Dec 20081:13 pmPRNChange of Adviser
19th Nov 20087:00 amPRNHalf-yearly Report
6th Aug 200812:58 pmPRNResult of General Meeting
6th Aug 200812:55 pmPRNDirectorate Changes
6th Aug 200812:52 pmPRNResult of AGM
11th Jul 20081:09 pmPRNNotice of General Meeting
3rd Jul 200812:34 pmPRNDirector/PDMR Dealing
24th Jun 20087:00 amPRNFinal Results
7th Apr 200811:47 amPRNAdviser change of name
28th Mar 20084:03 pmPRNStatement re Dual Listing
20th Mar 20087:00 amPRNDirector/PDMR Shareholding
29th Feb 20087:30 amPRNTotal Voting Rights
25th Feb 20087:00 amPRNFurther re Acquisition
14th Feb 200811:10 amPRNFurther re issue of equity
12th Feb 20087:00 amPRNIssue of Equity
11th Feb 20088:41 amPRNChange of Adviser
7th Feb 200811:18 amPRNResult of EGM
21st Jan 20082:37 pmRNSSchedule 1-Cubus Lux plc
15th Jan 20087:30 amRNSRestoration - Cubus Lux plx
15th Jan 20087:30 amPRNPosting of Admission Document
24th Dec 200711:00 amRNSSuspension - Cubus Lux plc
24th Dec 200711:00 amPRNExercise of Option and Temporary Suspension
26th Nov 20077:00 amPRNHalf-yearly Report
1st Oct 20073:14 pmPRNExtension of option agreements
28th Sep 20077:30 amPRNTotal Voting Rights
24th Sep 200711:09 amPRNAppointment of Joint Broker
21st Sep 20077:00 amPRNDirector/PDMR Shareholding
31st Aug 20072:45 pmPRNAGM Statement
17th Aug 20073:59 pmPRNAIM Rule 26 - Company Website
8th Aug 200712:46 pmPRNFurther re: Board Appointments
13th Jul 20077:30 amPRNExtension of option agreements
26th Jun 20077:00 amPRNFinal Results
21st May 200712:00 pmRNSRestoration - Cubus Lux plc
21st May 200712:00 pmRNSChange of Adviser
18th May 20074:41 pmRNSDirectorate Change
15th May 20077:02 amRNSSuspension - Cubus Lux plc
15th May 20077:02 amRNSStatement re. Suspension
3rd May 20072:00 pmRNSPlacing
19th Mar 20077:01 amRNSAgreement
13th Mar 200710:18 amRNSOption Agreement
5th Feb 20077:00 amRNSRe Agreement
24th Jan 20077:01 amRNSTotal Voting Rights
15th Jan 20077:00 amRNSPlacing
3rd Jan 200710:50 amRNSNew Accounting Ref Date
27th Dec 20068:56 amRNSTotal Voting Rights
27th Dec 20068:56 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.